Low alanine transaminase is not associated with increased rate of mortality in patients with advanced lung cancer

Amir Dagan, Tal Sella, Demian Urban, Yair Bar, Amir Onn, Gad Segal

Abstract


Background: Low alanine transaminase (ALT) has been shown to serve as a marker for sarcopenia and frailty in both healthy populations and in patients with chronic illness. Its yield in cancer patients in general and in particular in lung-cancer patients was not assessed.

Methods: Lung cancer patients presenting to an outpatient thoracic oncology clinic in a tertiary hospital were included. ALT plasma levels as well as other potential prognostic factors were collected retrospectively. Associations of those factors with survival were examined by univariate and multivariate analyses.

Results: 203 patients were eligible for analysis, of which 149 (73.4%) were diagnosed to have advanced disease. During median follow-up period of 15.4 months, 79 (38.9%) died. The mean ALT level of activity was 17.53±7.8 IU/L. The following parameters were found to be associated with increased risk of mortality: histologic type, male gender, advanced disease and low performance status upon diagnosis. Low ALT levels were not found to be associated with increased risk of mortality.

Conclusion: Low ALT activity levels, associated with sarcopenia, frailty and shortened survival in other patients' populations might not be predictive for shortened survival in lung cancer patients.  


Full Text:

PDF

References


Dempke WCM. Targeted Therapy for NSCLC-A Double-edged Sword? Anticancer Res [Internet]. 2015 May [cited 2015 May 18];35(5):2503–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25964523

Petrelli F, Coinu A, Cabiddu M, Borgonovo K, Ghilardi M, Lonati V, et al. Efficacy of fourth-line chemotherapy in advanced non-small-cell lung cancer: a systematic review and pooled analysis of published studies. Anticancer Drugs [Internet]. 2015 May 25 [cited 2015 Jun 5]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/26020807

Scagliotti G V, Bironzo P, Vansteenkiste JF. Addressing the unmet need in lung cancer: The potential of immuno-oncology. Cancer Treat Rev [Internet]. 2015 Apr 9 [cited 2015 May 29];41(6):465–75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25936526

Korc-Grodzicki B, Downey RJ, Shahrokni A, Kingham TP, Patel SG, Audisio RA. Surgical considerations in older adults with cancer. J Clin Oncol [Internet]. 2014 Aug 20 [cited 2015 Jul 24];32(24):2647–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25071124

Ramati E, Israel A, Tal Kessler, Petz-Sinuani N, Sela B-A, Idan Goren, et al. [Low ALT activity amongst patients hospitalized in internal medicine wards is a widespread phenomenon associated with low vitamin B6 levels in their blood]. Harefuah [Internet]. 2015 Feb [cited 2015 Jun 5];154(2):89–93, 137. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25856859

Ramaty E, Maor E, Peltz-Sinvani N, Brom A, Grinfeld A, Kivity S, et al. Low ALT blood levels predict long-term all-cause mortality among adults. A historical prospective cohort study. Eur J Intern Med [Internet]. 2014 Dec [cited 2015 Jun 5];25(10):919–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25468741

Ruhl CE, Everhart JE. The association of low serum alanine aminotransferase activity with mortality in the US population. Am J Epidemiol [Internet]. 2013 Dec 15 [cited 2015 May 14];178(12):1702–11. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3858105&tool=pmcentrez&rendertype=abstract

Le Couteur DG, Blyth FM, Creasey HM, Handelsman DJ, Naganathan V, Sambrook PN, et al. The Association of Alanine Transaminase With Aging, Frailty, and Mortality. Journals Gerontol Ser A Biol Sci Med Sci [Internet]. 2010 May 24 [cited 2015 Apr 14];65A(7):712–7. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4085878&tool=pmcentrez&rendertype=abstract

Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst [Internet]. 1980 Jul [cited 2015 Jul 11];65(1):25–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6930515

Espinosa E, Feliu J, Zamora P, González Barón M, Sánchez JJ, Ordón ez A, et al. Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. Lung Cancer [Internet]. 1995 Mar [cited 2015 Jul 11];12(1-2):67–76. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7600032

Goodwin JS, Hunt WC, Key CR, Samet JM. The effect of marital status on stage, treatment, and survival of cancer patients. JAMA [Internet]. 1987 Dec 4 [cited 2015 Jul 11];258(21):3125–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3669259

Ramaty E, Maor E, Peltz-Sinvani N, Brom A, Grinfeld A, Kivity S, et al. Low ALT blood levels predict long-term all-cause mortality among adults. A historical prospective cohort study. Eur J Intern Med [Internet]. 2014 Dec [cited 2015 Jun 5];25(10):919–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25468741

Jha SR, Ha HSK, Hickman LD, Hannu M, Davidson PM, Macdonald PS, et al. Frailty in advanced heart failure: a systematic review. Heart Fail Rev [Internet]. 2015 May 16 [cited 2015 Jun 7]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/25982016

Lee SJ, Son H, Shin SK. Influence of frailty on health-related quality of life in pre-dialysis patients with chronic kidney disease in Korea: a cross-sectional study. Health Qual Life Outcomes [Internet]. 2015 May 29 [cited 2015 Jun 7];13(1):70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26021987

Keevil VL, Romero-Ortuno R. Ageing well: a review of sarcopenia and frailty. Proc Nutr Soc [Internet]. 2015 May 25 [cited 2015 May 27];1–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26004622

Alvarez-Ríos AI, Guerrero JM, García-García FJ, Rodríguez-Mañas L, Medrano-Campillo P, de la Torre Lanza MA, et al. Associations between frailty and serum N-terminal propeptide of type I procollagen and 25-hydroxyvitamin D in older Spanish women: The Toledo Study for Healthy Aging. Exp Gerontol [Internet]. 2015 May 30 [cited 2015 Jun 7]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/26031553

Brouwers B, Dalmasso B, Hatse S, Laenen A, Kenis C, Swerts E, et al. Biological ageing and frailty markers in breast cancer patients. Aging (Albany NY) [Internet]. 2015 May 15 [cited 2015 Jun 7]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/25989735

Sastre J, Massuti B, Pulido G, Guillén-Ponce C, Benavides M, Manzano JL, et al. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. Eur J Cancer [Internet]. 2015 May 8 [cited 2015 Jun 7]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/25963019

Soares M, Toffart A-C, Timsit J-F, Burghi G, Irrazábal C, Pattison N, et al. Intensive care in patients with lung cancer: a multinational study. Ann Oncol [Internet]. 2014 Sep [cited 2015 Jun 7];25(9):1829–35. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24950981

Ramati E, Israel A, Tal Kessler, Petz-Sinuani N, Sela B-A, Idan Goren, et al. [Low ALT activity amongst patients hospitalized in internal medicine wards is a widespread phenomenon associated with low vitamin B6 levels in their blood]. Harefuah [Internet]. 2015 Feb [cited 2015 Jun 5];154(2):89–93, 137. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25856859

Ono K, Ono T, Matsumata T. The pathogenesis of decreased aspartate aminotransferase and alanine aminotransferase activity in the plasma of hemodialysis patients: the role of vitamin B6 deficiency. Clin Nephrol [Internet]. 1995 Jun [cited 2015 Jul 5];43(6):405–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7554526

Yasuda K, Okuda K, Endo N, Ishiwatari Y, Ikeda R, Hayashi H, et al. Hypoaminotransferasemia in patients undergoing long-term hemodialysis: clinical and biochemical appraisal. Gastroenterology [Internet]. 1995 Oct [cited 2015 Jul 5];109(4):1295–300. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7557098

Bertoldi M. Mammalian Dopa decarboxylase: structure, catalytic activity and inhibition. Arch Biochem Biophys [Internet]. 2014 Mar 15 [cited 2015 May 20];546:1–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24407024




DOI: http://dx.doi.org/10.17987/jcsm-cr.v2i1.16

Refbacks

  • There are currently no refbacks.